Discover the Latest in Biomedical Research Innovation

A former FDA reviewer ran a test for us. He took a real problem — a device with an endotoxin level his team couldn't lower — and tried to bait four AIs into approving a workaround he knew was wrong. One by one, ChatGPT, Gemini, and Claude came around and told him to proceed. Sophie refused: it cited the guidelines, held the line when he pushed, and sent him to the FDA. In regulated work, an AI eager to agree is a liability. Here's what happened — plus a test you can run yours

Stop drowning in data and start building a case. Most preclinical failures aren't technical—they're architectural. Discover why "Evidence Architecture" is the missing framework your biotech needs to survive FDA scrutiny, and hear about the rumored AI breakthrough from CLYTE that could change the game forever.